Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

Shares of ONVO opened at $0.41 on Tuesday. Organovo has a one year low of $0.32 and a one year high of $1.83. The stock has a market capitalization of $7.04 million, a price-to-earnings ratio of -0.48 and a beta of 0.45. The stock has a 50 day moving average price of $0.44 and a 200 day moving average price of $0.45.

Organovo (NASDAQ:ONVO) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. On average, analysts predict that Organovo will post -0.77 earnings per share for the current year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.